Previous 10 | Next 10 |
Syneos Health (SYNH): Q1 Non-GAAP EPS of $0.79 beats by $0.05; GAAP EPS of $0.37 beats by $0.13.Revenue of $1.21B (+4.3% Y/Y) beats by $20M.Press Release For further details see: Syneos Health EPS beats by $0.05, beats on revenue
Highlights Revenue of $1,208.7 million for the three months ended March 31, 2021, representing a sequential increase of 6.0% compared to the three months ended December 31, 2020, and a year-over-year increase of 3.9% compared to the three months ended March 31, 2020. Net new...
Syneos Health (NASDAQ:SYNH) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is $0.74 (+8.8% Y/Y) and the consensus Revenue Estimate is $1.19B (+2.6% Y/Y).Over the last 2 years, SYNH has beaten EPS estimates 88% of the time an...
Syneos Health Inc. (NASDAQ:SYNH) traded at a new 52-week high today of $89.46. So far today approximately 176,000 shares have been exchanged, as compared to an average 30-day volume of 939,000 shares. Syneos is a global contract research and outsourced commercialization organization that...
An influx of news into healthcare's contract research organization sector is calling for a re-rating, Baird says in looking at its preferred picks headed into Q1 earnings. First came an activist stake in Laboratory Corp. of America (LH) to press for strategic alternatives. That was followed b...
MORRISVILLE, N.C. and PALO ALTO, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Medable, the leading cloud platform for patient-centered drug development, today announced a strat...
Icon plc (ICLR) said it won HSR approval for its planned purchase of PRA Health (PRAH).Icon confirmed winning regulatory approval for the PRA deal in an email to Seeking Alpha. The HSR deadline expired for the deal expired yesterday.Earlier today Icon peer PPD (PPD) agreed to a sale of the co...
Syneos Health Inc. (NASDAQ:SYNH) traded today at a new 52-week high of $84.33. This new high was reached on below average trading volume as 176,000 shares traded hands, while the average 30-day volume is approximately 975,000 shares. In the past 52 weeks, shares of Syneos Health Inc. hav...
Syneos Health (SYNH) rose 5.2% following Thermo's Fisher (TMO) planned acquisition of PPD Inc. (PPD)Syneos Health is a per of PPD and in May Reuters reported that the contract research organization was exploring a sale.Other CRO Charles River Labs (CRL) rose 2.5%, while La...
MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET. ...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...